Zolbetuximab

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Zolbetuximab (IMAB362) 是一种靶向 Claudin-18.2 的单克隆抗体。Zolbetuximab 通过免疫效应机制介导对 Claudin-18.2 阳性细胞的特异性杀伤。Zolbetuximab 可用于胃肠道腺癌和胰腺肿瘤的研究。

Zolbetuximab (IMAB362) is a monoclonal antibody targeting Claudin-18.2. Zolbetuximab mediates specific killing of Claudin-18.2-positive cells through immune effector mechanisms. Zolbetuximab can be used for the research of gastrointestinal adenocarcinomas and pancreatic tumors.

——

Animal Model:mouse BxPC-3-CLDN18.2, MIA PaCa-2-CLDN18.2 xenograft model Dosage:200 μg alone or with 50 mg/kg Gemcitabine Administration:i.v.; i.p. (Gemcitabine)Result:Inhibited tumor growth in two models, and prevented lung metastasis formation.Prolonged survival time, and lowered fractions of CLDN18.2+ cells in MIA PaCa-2-CLDN18.2 xenograft.

——

Others

Other Targets

Others

——

——

1496553-00-4

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years